Inspire Medical Systems (NYSE:INSP) Price Target Cut to $50.00 by Analysts at Truist Financial

Key Points

• Truist cut its price target on Inspire from $64 to $50 and assigned a "hold," part of a broader round of analyst price-target cuts that leaves the stock with an average rating of "Hold."
• Management sharply lowered FY2026 guidance to $0.75–$1.25 EPS and $825M–$875M revenue, citing reimbursement/coding issues and WISeR disruption, which triggered a steep intraday sell-off and a 15.9% drop to $46.14.
• Q1 results beat estimates — Inspire reported $0.10 EPS (vs. a -$0.28 consensus) and $204.6M revenue, showing modest year-over-year growth despite the weaker outlook.

Inspire Medical Systems (NYSE:INSP - Get Free Report) had its target price dropped by analysts at Truist Financial from $64.00 to $50.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a "hold" rating on the stock. Truist Financial's price objective suggests a potential upside of 8.37% from the stock's previous close.

INSP has been the subject of several other research reports. Piper Sandler lowered shares of Inspire Medical Systems from an "overweight" rating to a "neutral" rating and set a $55.00 target price for the company. in a research note on Tuesday. Robert W. Baird reduced their price target on shares of Inspire Medical Systems from $63.00 to $50.00 and set a "neutral" rating for the company in a report on Tuesday. Jefferies Financial Group reduced their price target on shares of Inspire Medical Systems from $81.00 to $66.00 and set a "hold" rating for the company in a report on Thursday, February 12th. Stifel Nicolaus reduced their price target on shares of Inspire Medical Systems from $85.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 10th. Finally, Wolfe Research downgraded shares of Inspire Medical Systems from an "outperform" rating to a "peer perform" rating in a report on Friday, February 13th. Four research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Inspire Medical Systems has an average rating of "Hold" and an average price target of $93.33.

Inspire Medical Systems Stock Down 15.9%

INSP stock traded down $8.70 during trading on Tuesday, hitting $46.14. 1,157,460 shares of the company's stock traded hands, compared to its average volume of 1,176,709. Inspire Medical Systems has a 52 week low of $44.41 and a 52 week high of $163.35. The stock has a fifty day moving average price of $56.73 and a two-hundred day moving average price of $79.64. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of 9.24, a price-to-earnings-growth ratio of 2.92 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. The firm had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, equities research analysts expect that Inspire Medical Systems will post 1.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Inspire Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of the company. Xponance Inc. boosted its holdings in shares of Inspire Medical Systems by 2.9% during the third quarter. Xponance Inc. now owns 4,177 shares of the company's stock valued at $310,000 after acquiring an additional 116 shares during the period. Daiwa Securities Group Inc. lifted its holdings in Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company's stock worth $60,000 after purchasing an additional 130 shares during the period. State of Wyoming lifted its holdings in Inspire Medical Systems by 31.5% in the fourth quarter. State of Wyoming now owns 731 shares of the company's stock worth $67,000 after purchasing an additional 175 shares during the period. Smartleaf Asset Management LLC lifted its holdings in Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock worth $42,000 after purchasing an additional 205 shares during the period. Finally, Apollon Wealth Management LLC lifted its holdings in Inspire Medical Systems by 5.6% in the first quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company's stock worth $206,000 after purchasing an additional 212 shares during the period. Institutional investors and hedge funds own 94.91% of the company's stock.

More Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS (vs. consensus loss) and $204.6M revenue, topping Street expectations and showing modest year-over-year sales growth. This supports the company's underlying business strength. GlobeNewswire: Q1 Results
• Neutral Sentiment: Analyst note: Mizuho cut its price target from $70 to $55 but kept an "outperform" rating — the new target offers almost no upside versus the current price, so it is mixed (still favorable rating but lower conviction on upside). Benzinga
• Neutral Sentiment: Company materials and call transcript are available for investors reviewing management commentary and the details behind the guidance change. Earnings Call Summary (Yahoo)
• Negative Sentiment: Guidance cut — Inspire narrowed FY2026 EPS guidance to $0.75–$1.25 (street ~$1.99) and revenue to $825M–$875M (street ~$961M). Management cited reimbursement/coding issues and WISeR disruption as drivers of the downgrade, which materially reduces expected growth and margins. Seeking Alpha: Guidance & WISeR Disruption
• Negative Sentiment: Analyst downgrades/price-target cuts — Robert W. Baird cut its target to $50 and moved to "neutral"; Bank of America reaffirmed "neutral" with a $53 target. Those moves signal reduced analyst confidence and put further pressure on the shares. The Fly: Baird Note
• Negative Sentiment: Market reaction: coverage and headlines emphasizing the guidance cut and reimbursement uncertainty drove a sharp intraday sell-off (coverage noted a large single-day decline following the update). Yahoo Finance: Stock Reaction

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.